JPM24: Bristol Myers Squibb CEO Boerner emphasizes organic pipeline over recent M&A deals

It took Bristol Myers Squibb’s new CEO Chris Boerner 16 minutes into his 24-minute presentation to address the big news the company made last month, with its holiday buyouts of Karuna Therapeutics, for $14 billion, and RayzeBio, for $4.1 billion.